|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,690 KRW | -0.14% |
|
-0.54% | -20.99% |
Qurient Co. Ltd. announced that the first patient has been dosed in the Phase 1/2 dose-escalation and expansion study of Q901 in patients with advanced solid tumors. The Q901 Phase 1/2 study (NCT05394103) is being conducted at six investigative sites in the U.S., and approximately 70 patients with advanced solid tumors are scheduled to be enrolled.
The primary objectives of the Phase 1/2 study are to determine the maximum tolerated dose, safety profile, and anticancer efficacy of Q901.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.99% | 87.47M | |
| +29.50% | 77.77B | |
| +0.30% | 24.62B | |
| +14.70% | 8.75B | |
| +0.73% | 8.35B | |
| -28.87% | 7.1B | |
| +16.06% | 5.25B | |
| +1.58% | 4.1B | |
| -8.90% | 3.8B | |
| -7.62% | 3.39B |
QURIENT CO., LTD. 
